Jeffrey W. Albers is of Blueprint Medicines Corp. Currently has a direct ownership of 157,557 shares of BPMC, which is worth approximately $14 Million. The most recent transaction as insider was on Aug 25, 2023, when has been sold 10,000 shares (Common Stock) at a price of $1.87 per share, resulting in proceeds of $18,700. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 158K
5.8% 3M change
10.5% 12M change
Total Value Held $14 Million

Jeffrey W. Albers Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 25 2023
BUY
Exercise of conversion of derivative security
$18,700 $1.87 p/Share
10,000 Added 5.1%
186,050 Common Stock
Aug 24 2023
SELL
Open market or private sale
$743,550 $49.57 p/Share
15,000 Reduced 7.85%
176,050 Common Stock
Aug 24 2023
BUY
Exercise of conversion of derivative security
$28,050 $1.87 p/Share
15,000 Added 7.28%
191,050 Common Stock
Jun 21 2023
BUY
Grant, award, or other acquisition
-
2,600 Added 1.46%
176,050 Common Stock
Mar 06 2023
SELL
Open market or private sale
$440,685 $45.0 p/Share
9,793 Reduced 5.34%
173,450 Common Stock
Dec 05 2022
SELL
Open market or private sale
$1,001,800 $50.09 p/Share
20,000 Reduced 9.84%
183,243 Common Stock
Dec 05 2022
BUY
Exercise of conversion of derivative security
$168,800 $8.44 p/Share
20,000 Added 8.96%
203,243 Common Stock
Aug 22 2022
SELL
Open market or private sale
$596,185 $70.89 p/Share
8,410 Reduced 4.39%
183,243 Common Stock
Aug 22 2022
BUY
Exercise of conversion of derivative security
$126,234 $15.01 p/Share
8,410 Added 4.2%
191,653 Common Stock
Aug 19 2022
SELL
Open market or private sale
$111,332 $70.02 p/Share
1,590 Reduced 0.86%
183,243 Common Stock
Aug 19 2022
BUY
Exercise of conversion of derivative security
$23,866 $15.01 p/Share
1,590 Added 0.85%
184,833 Common Stock
Aug 16 2022
SELL
Open market or private sale
$1,374,400 $68.72 p/Share
20,000 Reduced 9.84%
183,243 Common Stock
Aug 16 2022
BUY
Exercise of conversion of derivative security
$168,800 $8.44 p/Share
20,000 Added 8.96%
203,243 Common Stock
Aug 08 2022
SELL
Open market or private sale
$700,700 $70.07 p/Share
10,000 Reduced 5.17%
183,243 Common Stock
Aug 08 2022
BUY
Exercise of conversion of derivative security
$53,400 $5.34 p/Share
10,000 Added 4.92%
193,243 Common Stock
May 16 2022
SELL
Open market or private sale
$1,108,800 $55.44 p/Share
20,000 Reduced 9.84%
183,243 Common Stock
May 16 2022
BUY
Exercise of conversion of derivative security
$168,800 $8.44 p/Share
20,000 Added 8.96%
203,243 Common Stock
Apr 06 2022
SELL
Open market or private sale
$350,550 $70.11 p/Share
5,000 Reduced 2.66%
183,243 Common Stock
Apr 06 2022
BUY
Exercise of conversion of derivative security
$75,050 $15.01 p/Share
5,000 Added 2.59%
188,243 Common Stock
Mar 07 2022
SELL
Open market or private sale
$272,128 $56.19 p/Share
4,843 Reduced 2.57%
183,243 Common Stock
Mar 04 2022
SELL
Open market or private sale
$1,160,000 $58.0 p/Share
20,000 Reduced 9.61%
188,086 Common Stock
Mar 04 2022
BUY
Exercise of conversion of derivative security
$168,800 $8.44 p/Share
20,000 Added 8.77%
208,086 Common Stock
Mar 03 2022
SELL
Open market or private sale
$473,921 $60.28 p/Share
7,862 Reduced 4.01%
188,086 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
7,500 Added 3.69%
195,948 Common Stock
Nov 15 2021
SELL
Open market or private sale
$3,405,300 $113.51 p/Share
30,000 Reduced 13.73%
188,448 Common Stock

Also insider at

MGTA
Magenta Therapeutics, Inc. Healthcare
KYMR
Kymera Therapeutics, Inc. Healthcare
AGLE
Aeglea BioTherapeutics, Inc. Healthcare
JWA

Jeffrey W. Albers

Cambridge, MA

Track Institutional and Insider Activities on BPMC

Follow Blueprint Medicines Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

News

Receive news related to Blueprint Medicines Corp

Track Activities on BPMC